PROPEL Contour receives CE mark. Click here to learn more.
Fiagon AG Medical Technologies is now part of Intersect ENT – Click here to learn more about our navigation offering.

About Intersect ENT

Intersect ENT (NASDAQ: XENT) is a medical technology company dedicated to advancing the treatment of ear, nose and throat (ENT) conditions through evidence-based innovation, providing physicians with solutions to overcome clinical challenges and improve the quality of life for patients.

Intersect ENT’s initial focus is on improving the treatment of chronic sinusitis, an inflammatory condition that affects one out of eight adults in the U.S. and has a greater impact on quality of life than congestive heart failure or chronic back pain.1,2 Chronic sinusitis often requires a complex combination of medical and surgical therapy and is hence one of the most costly conditions to U.S. employers3. While traditional surgical solutions relieve symptoms in many patients, disease recurrence is frequent with the majority of patients experiencing recurrent symptoms within the first year.4

Intersect ENT is a publicly traded company.

OUR VALUES

Empowerment

We make things happen. Decisive, supportive, trusting, accountable.

Integrity

We do the right thing. Honest, ethical, thorough.

Respect

We assume noble intent. Flexibility, candor, dignity.

Collaboration

We are a team. Diversity of thought, cooperation, partnership, transparency.

Innovation

We embrace complexity – we figure it out. Undaunted, first in class, transformative.

LEADERSHIP TEAM

Thomas A. West

President and Chief Executive Officer

biography

Tom was named Chief Executive Officer and a member of the Board of Directors in July 2019. Previously, he served as Division President, Diagnostics Solutions at Hologic, Inc. At Hologic, he delivered consistent,above-market revenue growth rates in the domestic and international diagnostics business, achieving over $1.1 billion in worldwide diagnostics sales and reversing previous declines. Prior to Hologic, Tom held various roles of increasing responsibility at Johnson & Johnson, including serving as Worldwide Vice President of Strategy and Business Development for Johnson & Johnson’s Diabetes Solutions Companies. He also served as President of LifeScan North America and as President of LifeScan EMEA. Tom earned a Bachelor’s degree in politics and economics from Princeton University and a Master of Business Administration from the Wharton School at the University of Pennsylvania.

Randy Meier

Richard (Randy) A. Meier

Executive Vice President & Chief Financial Officer

biography

Randy joined Intersect ENT in November 2019 as Executive Vice-President and Chief Financial Officer. Previously he served in various senior executive leadership positions at Owens & Minor, Inc. a global healthcare services company, including Chief Financial Officer, President-International and Executive Vice President. Prior to joining Owens and Minor, Randy served as Executive Vice President and Chief Financial Officer at Teleflex, Inc., a global medical device company. Randy held the position of President and Chief Operating Officer of Advanced Medical Optics, Inc., a global ophthalmic medical device company, when the company was acquired as a wholly owned subsidiary of Abbott Laboratories. He joined Advanced Medical Optics as Corporate Vice President and Chief Financial Officer in 2002. Randy was also a member of ICN Pharmaceuticals executive leadership team where he served as Executive Vice President and Chief Financial Officer, and as Treasurer. Randy earned a bachelor’s degree in economics from Princeton University.

Patrick Broderick

Patrick Broderick

Executive Vice President, General Counsel and Corporate Secretary

biography

Patrick joined Intersect ENT in 2020 as Executive Vice President, General Counsel and Corporate Secretary.  Prior to joining Intersect ENT, he served as General Counsel, Chief Compliance Officer and Secretary at Grail, Inc., a position he occupied for two years.  Prior to working at Grail, Patrick led the legal department supporting McKesson Corporation’s $200bn annual revenue pharmaceutical distribution business.  Patrick previously held the position of Senior Vice President at several smaller Bay Area bio-techs, including COR Therapeutics.  Patrick is a graduate of Harvard University and Yale Law School.

reyna fernandez

Reyna Fernandez

Chief Human Resources Officer

biography

Reyna joined Intersect ENT in 2020 as Chief Human Resources Officer.  Prior to joining Intersect ENT, she served as Chief Human Resources Officer at Endologix.  Reyna brings a depth of experience in human resources within the health care industry both in medical devices and pharmaceutical sectors.  In addition to working in Bristol Myers Squibb, Reyna held the position of Vice President of Human Resources both at Canon Medical Systems and ten years at Johnson & Johnson in Ethicon, Inc. and Advanced Sterilization Products (ASP).   She has a passion for developing talent with a focus on organization design, employee engagement, coaching, talent development, diversity and inclusion.  Reyna is a Professional Certified Coach with the International Coaching Federation (ICF) and founded her own human resources and executive coaching consultancy, a role that gave her exposure to a variety of healthcare and non-healthcare companies.  Reyna is a graduate of Haverford College and has a Master of Social Administration from Columbia University.

COMPLIANCE OVERVIEW

Intersect ENT, Inc. declares that, as part of our continued focus on compliance, we have developed a Comprehensive Compliance Program that, to the best of our knowledge and as of the date of this declaration, substantially complies with the requirements of California Health & Safety Code §§ 119400- 119402. Copies of this declaration may be obtained by calling 866-531-6004.  June 1, 2021

1National Health Interview Survey 2006. CDC National Center for Health Statistics. Series 10 Number 235.
2Gliklich et al. Otolaryngol Head Neck Surg. 1995;113:104-9.
3Rudmik L et al. Curr Allergy Asthma Rep. 2017;17:20.
4Shaitkin et al. Laryngoscope. 103 Oct 2003.